Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Leqselvi is a medicine used to treat severe alopecia areata, manufactured by Sun Pharmaceutical. The generic name of the drug ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

Leqselvi, part of Sun’s dermatology portfolio, was previously blocked from launch by a court order in November 2024.

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...